{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T04:42:18Z","timestamp":1750653738008},"reference-count":22,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":1303,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[1998,6]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>In spite of its frequent use in the treatment of irritable bowel disease little is known about mebeverine\u2019s mode of action in man.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p>To examine mebeverine\u2019s effect on transit though the gut during lactulose\u2010induced diarrhoea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Nine healthy volunteers undertook a two\u2010way randomized crossover study. Diarrhoea was induced using lactulose pre\u2010treatment (20\u2003m t.d.s., 4\u2003days) and subjects received either mebeverine (135\u2003mg t.d.s.) or no treatment. Transit of two enteric\u2010coated capsules containing radiolabelled 8.4\u2003mm tablets and 180\u2013250\u2003\u03bc<jats:sc>M<\/jats:sc> ion exchange resin were followed using gamma scintigraphy. Stool frequency and symptoms were assessed by diary cards.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Mebeverine reduced mean daily stool frequency associated with lactulose ingestion from a median of 2.25 (interquartile range (IQR) 1.75\u20132.75) to 1.5 (IQR 1.25\u20132.25) movements. Mebeverine significantly reduced the number of mass movements observed in the colon during the 11\u2003h of the study from 2 (2\u20132) to 1 (1\u20132), and the number of retrograde movements from 1 (0\u20132) to 0 (0\u20130) (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.05). Mebeverine did not significantly alter the gastric emptying rate of the intact capsule (2.9 (1.9\u20133.2) to 2.8 (2.6\u20134.0)\u2003h) however it induced a small but significant acceleration in small intestinal transit of the capsule (1.6 (0.8\u20132.0)\u2003h to 1.0 (0.52\u20131.32)\u2003h, <jats:italic>P<\/jats:italic>\u2003=\u20030.02).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Mebeverine reduces the diarrhoeal effect of lactulose by decreasing the mass movements induced in the ascending colon. This effect may contribute to its clinical effect in irritable bowel syndrome.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.1998.00340.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:36:51Z","timestamp":1047353811000},"page":"583-588","source":"Crossref","is-referenced-by-count":6,"title":["Mebeverine decreases mass movements and stool frequency in lactulose\u2010induced diarrhoea"],"prefix":"10.1111","volume":"12","author":[{"family":"Washington","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Ridley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Spiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Watts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"159","article-title":"Identification of subgroups of functional gastrointestinal disorders","volume":"3","author":"Drossman DA","year":"1990","journal-title":"Gastroenterol Int"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6138.653"},{"key":"e_1_2_6_4_2","first-page":"232","article-title":"Mebeverine in patients with irritable colon syndrome","volume":"77","author":"Tasman\u2010Jones C","year":"1973","journal-title":"NZ Med J"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1159\/000199329"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(88)90319-8"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(87)90594-2"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9260(82)80257-2"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.34.6.799"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)91500-4"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1982.tb02419.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006231-198504000-00005"},{"key":"e_1_2_6_13_2","unstructured":"WashingtonN HarrisM MussellwhiteA GreavesJL WilsonCG SpillerRC. Viscous fibre delays oro\u2010caexcal transit during lactulose induced diarrhoea: impact on transit through the assending colon. Gut (Suppl.) 1992; F277 (Abstract)."},{"key":"e_1_2_6_14_2","first-page":"504","article-title":"Impaired colonic motor response to eating in patients with slow\u2010transit constipation","volume":"87","author":"Bassotti G","year":"1992","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.28.1.17"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.30.8.1099"},{"key":"e_1_2_6_17_2","unstructured":"JonesVA McLaughlanP ShorthouseM WorkmanE HunterJO.Food intolerance: a major factor in the pathogenesis of irritable bowel syndrome. Lancet1982; ii:111517."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529209000167"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111738"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)91789-7"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(93)90941-5"},{"key":"e_1_2_6_22_2","article-title":"Colonic distribution of daily dosed, radiolabelled resin: right sided reservoir and left sided conduit","volume":"37","author":"Hedben JM","year":"1995","journal-title":"Gut"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1996.61203000.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1998.00340.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1998.00340.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.1998.00340.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T09:26:28Z","timestamp":1694424388000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.1998.00340.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1998,6]]}},"alternative-id":["10.1046\/j.1365-2036.1998.00340.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.1998.00340.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,6]]}}}